AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04042324
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH): a common anticoagulant used during hemodialysis treatments.
Trial: NCT02804126
Drug: Ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day
Trial: NCT00889512
Drug: Luveris fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luveris 75IU daily throughout ovarian stimulation
Trial: NCT01390402
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 mg/m2 by vein Days 1, 3 and 6 post transplant.
Trial: NCT00746863
Drug: 0.125% Marcaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to the intervention arm will receive 60 cc of 0.125% Marcaine injected into the retropubic space along the tract that the suprapubic mid-urethral trocar will follow (one on each side) for a total of 120 cc of 0.125% Marcaine, prior to the placement of the mid-urethral sling via the suprapubic approach.
Trial: NCT02737124
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen will be given 24 hours before scheduled surgery.
Trial: NCT01066728
Drug: Theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00655629
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive 12 weeks of PRN (on demand) treatment with matching placebo tablet
Trial: NCT00654082
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet by mouth 1 hour prior to anticipated sexual activity, but not more than once daily (QD) for 6 weeks
Trial: NCT00534924
Drug: Vit C
RxNorm normalized name: M-Vit Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02511886
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched tablets
Trial: NCT01301313
Drug: Conventional intensified inotropic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing the dose and / or the number of inotropes (dopamine and / or dobutamine and / or milrinone and / or adrenaline)
Trial: NCT00003727
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01776606
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, Dose B; dose applied to the lateral canthal lines
Trial: NCT00047515
Drug: Alcon Investigational Agent
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04252261
Drug: placedo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To evaluate the effects of sulforaphane on the cognitive improvement of patients with frontal brain damage
Trial: NCT02456454
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01091142
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1: placebo Cohort 2: placebo Cohort 3: placebo Cohort 4: placebo
Trial: NCT03235947
Drug: Intravenous placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 0.9% 100 mL intravenous administered three times in the perioperative period of the renal transplant, at the same times corresponding to disodium fosfomycin
Trial: NCT00127179
Drug: Comparator: placebo / Duration of Treatment: 48 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02155777
Drug: OrthoNovum 1/35
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04533139
Drug: Influenza vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: influenza vaccine 0.5 ml intramuscularly each season~2004-2005 season antigens: A/New Caledonia/20/99(H1N1)-like, A/Wyoming/3/2003(H3N2), and B/Shanghai/361/2002-like antigens~2005-2006 season antigens: A/New Caledonia/ 20/00(H1N1)-like, A/California/7/2004 (H3N2)-like, and B/Shanghai/361/2002-like antigens
Trial: NCT00657163
Drug: fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: fluoxetine per os 20 mg daily
Trial: NCT00657163
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo per os daily
Trial: NCT02685033
Drug: Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04577469
Drug: Maldox tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
Trial: NCT04577469
Drug: G-COSPE® tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg sulfadoxine / 25 mg pyrimethamine to be given as single dose once under fasting condition
Trial: NCT00971074
Drug: Hylan G-F 20
RxNorm normalized name: hylan G-F 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 ml intra-articular injection given once. The injection takes approximately 15 seconds.
Trial: NCT03328117
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo oral capsule
Trial: NCT02124213
Drug: 30 mg PF-06412562
RxNorm normalized name: CODEINE PO4 30MG/ML (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will receive a single dose of 30 mg PF-06412562
Trial: NCT02008734
Drug: PD0332991
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01303835
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized patients received placebo to be taken every night before bed.
Trial: NCT00423007
Drug: Bromfenac
RxNorm normalized name: Bromfenac
DrugBank: Bromfenac (DB00963)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00423007
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01485328
Drug: AMARGOL®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: per oral solution, 40 mL single dose
Trial: NCT00566462
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for for 14 days followed by 4 mg/d for 14 days
Trial: NCT00832416
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One Placebo tablet daily.
Trial: NCT00058188
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT04523467
Drug: Anti-angiogenic Targeted Drugs
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A tyrosine kinase inhibitor inhibits vascular endothelial growth factor (VEGF) receptors 1-3, showed efficacy in hepatocellular carcinoma
Trial: NCT00856817
Drug: L-arginine + heme arginate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine first, heme arginate second three day treatment
Trial: NCT00856817
Drug: Heme arginate + L-arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heme arginate first, L-arginine second three day treatment
Trial: NCT02238158
Drug: Atrovent® inhalets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04776889
Drug: Rosuvastatin 20mg
RxNorm normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 20mg/day for 6 months added to bilateral subcapsular orchiectomy
Trial: NCT00693693
Drug: hydrocortisone 17-butyrate 0.1% Ointment preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply medication twice a day to affected areas of atopic dermatitis
Trial: NCT00693693
Drug: hydrocortisone 17-butyrate 0.1% Lipocream preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply medication twice a day to affected areas of atopic dermatitis
Trial: NCT01985750
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other Names:~comparison of d-cycloserine or placebo on enhancing the beneficial effects of pulmonary rehabilitation on breathlessness perception~250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation
Trial: NCT00087334
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02995473
Drug: NP000888
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 270 µg/g topical (BID) for 24 weeks
Trial: NCT02995473
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical (BID) for 24 weeks
Trial: NCT05060198
Drug: Artemether-lumefantrine (AL)
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL is the current first-line antimalarial in Kenya, per Kenya Ministry of Health.
Trial: NCT03934203
Drug: Placebo matching to BI 409306
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet
Trial: NCT03163173
Drug: GC4419
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg (\~100 μCi) dose of \[14C\]GC4419
Trial: NCT00995605
Drug: AMAP102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMAP102 or Placebo
Trial: NCT01810380
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily as tablets and capsules, orally
Trial: NCT01537133
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry Powder Inhaler: Placebo
Trial: NCT04356872
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ADM, 60mg/m2, iv, d1
Trial: NCT00876044
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous route
Trial: NCT04257851
Drug: Theophylline Anhydrous Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline tablet (150 mg/12h)
Trial: NCT04131829
Drug: Fluoxetine - delayed treatment
RxNorm normalized name: fluoxetine Delayed Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following the Baseline assessment, OCD subjects will be randomized to receive either immediate fluoxetine monotherapy or delayed fluoxetine, after a 6-week placebo lead-in.
Trial: NCT02915055
Drug: Ibuprofen 600 mg
RxNorm normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 600 mg to be taken every 8 hours (TID) as needed (PRN
Trial: NCT02915055
Drug: standard oxycodone/acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04619914
Drug: Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CLOMID (clomiphene citrate tablets USP) is an orally administered, nonsteroidal, ovulatory stimulant designated chemically as 2-\[p-(2-chloro-1,2-diphenylvinyl)phenoxy\] triethylamine citrate (1:1)
Trial: NCT01362491
Drug: Ibuprofen Sodium
RxNorm normalized name: Ibuprofen sodium
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single-dose of ibuprofen sodium tablets (equal to 400 mg ibuprofen)
Trial: NCT01362491
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose of placebo
Trial: NCT02491736
Drug: Ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5% ketoprofen gel
Trial: NCT03778593
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: D1 Leucovorin 400 mg/m2 + 5DW 200 ml mix IV over 2 hours q 2 weeks
Trial: NCT02337010
Drug: Vasopressor
RxNorm normalized name: Vasopressor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If hypotension was present it was treated with vasopressor as 10 mcg bolus or continuous infusion of norepinephrine (Arterenol® Sanofi, Germany).
Trial: NCT04479449
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be intravenously administered twice daily (intervals of 12 hours)
Trial: NCT02674347
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV matching the Investigational drug
Trial: NCT01749787
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered via infusion once per week for 5 weeks
Trial: NCT01159015
Drug: KetoNaph
RxNorm normalized name: Ketonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic Solution administered BID for 6 weeks
Trial: NCT01159015
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle of KetoNaph ophthalmic solution administered bid for six weeks
Trial: NCT04577430
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline is used to observe the effect on the electrophysiology of the patients' hearts
Trial: NCT01456169
Drug: Azilsartan medoxomil - chlorthalidone
RxNorm normalized name: azilsartan medoxomil / chlorthalidone Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azilsartan medoxomil and chlorthalidone fixed dose combination tablets
Trial: NCT01942174
Drug: Methotrexate - Immediate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: concerning immediate group, methotrexate is Initiated in the same time that the antipneumococcal vaccination by prevenar 13
Trial: NCT01942174
Drug: Methotrexate - Delay
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For period group, methotrexate is Initiated \& month after the antipneumococcal vaccination by prevenar 13
Trial: NCT01687101
Drug: STOPAIN topical gel
RxNorm normalized name: Stopain Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STOPAIN topical gel is topical menthol 6% gel applied as 2 to 4 pumps of gel applied behind the ears and to the occipital region of the neck in one or two applications within 2 hours of the onset of the migraine.
Trial: NCT02159976
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500mg bid
Trial: NCT02159976
Drug: Tetracycline
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracycline 1000mg bid
Trial: NCT01165294
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An intravenous bolus will be given in 5 minutes time followed by a 1 minute break after which a continuous infusion will start. Dosage lowered every 10 minutes
Trial: NCT02859103
Drug: Desvenlafaxine
RxNorm normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be provided 50mg dose of desvenlafaxine for 1 week titrated up to 100mg dose of desvenlafaxine for 7 weeks.
Trial: NCT00935311
Drug: ABT-712 Extended-release
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-712 extended-release tablet
Trial: NCT00935311
Drug: Hydrocodone/Acetaminophen Immediate-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone/acetaminophen immediate-release tablet
Trial: NCT00935311
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet
Trial: NCT00870012
Drug: Lepicol probiotic & prebiotic formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAFLD patients treated with Lepicol probiotic and prebiotic formula for 24 weeks.
Trial: NCT03539718
Drug: Taurolidine heparin
RxNorm normalized name: heparin / taurolidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taurolock-hep 500 at end of session
Trial: NCT03539718
Drug: Heparin Sodium
RxNorm normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin sodium 5000 at end of session
Trial: NCT02959697
Drug: Subcut. + Subconj. Xylocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will receive the standard subcutaneous local anesthetic as well as an additional subconjunctival injection of local anesthetic (Xylocaine).
Trial: NCT01006694
Drug: Guideline Antidepressant Medication
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline Antidepressant Medication, following the VN National Mental Health plan.
Trial: NCT04094857
Drug: HBN-1
RxNorm normalized name: Hydroxybutyrate-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT02259946
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01160263
Drug: SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 123 I-FP-CIT (DATSCAN) : 185 MBq (5 mCi), 2,5 ml will be injected via an arm intravenous catheter.~123I-ADAM:185 MBq,5 ml will be injected via an arm intravenous catheter.
Trial: NCT03920254
Drug: TD-1473 Dose A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See Arm description
Trial: NCT03920254
Drug: TD-1473 Dose B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See Arm description
Trial: NCT02045095
Drug: MLN7243
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation stage Schedule A: Intravenous infusion on Days 1, 4, 8, 11 for a 21-day treatment cycle.~Schedule B: Intravenous infusion on Days 1, 8, 15 for a 28-day treatment cycle.~Dose expansion stage: MLN7243 will be administered following schedule A (twice-weekly, 21-day dosing) and/or B (once-weekly, 28-day dosing).
Trial: NCT04031859
Drug: acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: It's a VTE risk stratification tool or procedure that will be used after total knee replacement (TKR) to help surgeons in choosing the tailored VTE prophylaxis according to patients' specific VTE risk, this tool will stratify the TKR-patient in one of three risk-groups: Low high risk who will be prescribed Aspirin upon hospital discharge as extended VTE prophylaxis post TKR surgery, or moderate high risk group who will be prescribed oral anti coagulant (like rivaroxaban) as extended prophylaxis, and the last group is very high risk group who will be prescribed parenteral anticoagulant ( like Enoxaparin) plus compression devices.
Trial: NCT02473900
Drug: HIP1403
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir 75mg
Trial: NCT02473900
Drug: HGP0919
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir phosphate 75mg
Trial: NCT02058251
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participant will self-administer a 40 IU dose of intranasal saline.
Trial: NCT00616772
Drug: ABT-335
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule
Trial: NCT00616772
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule
Trial: NCT01680939
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10mg/kg PO q6hrs
Trial: NCT00074867
Drug: CP-547,632
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02380742
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will then be positioned in dorsal lithotomy position with the use of stirrups. Two mL of placebo cream will be placed into the vagina and 2 mL will be spread on the perineum. The cream placed into the vagina will be introduced to the level of the pessary with the practitioners' finger. Once application is completed, a timer will be set for five minutes. After five minutes, the patient will again be placed into dorsal lithotomy position with the use of stirrups. The pessary will be removed per practitioners' usual practice. The patient will be asked to mark her pain score for at this point
Trial: NCT00580073
Drug: FOLFOX4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxaliplatin (85mg/m2 on days 1 and 15 of each cycle)+ 5FU Bolus (400mg/m2 on days 1, 2, 15, and 16 of each cycle) + 5FU CI (600mg/m2 on days 1, 2, 15, and 16 of each cycle) + Leucovorin (200mg/m2 on days 1, 2, 15, and 16 of each cycle)
Trial: NCT02223338
Drug: Standard Aseptic Technique
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group will have received Povidone-Iodine Only following injections of anti-VEGF agents at least 3 times in the last 6 months.
Trial: NCT03518112
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03518112
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03518112
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03518112
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT or IV
Trial: NCT02121314
Drug: intravenous administration of 1st line TB drugs, day 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TB drugs IV on day 1 for calculation of bioavailability while fasting or fed
Trial: NCT00570310
Drug: Comparator: Placebo (unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pregabalin Pbo (up to 600 mg/day by mouth (po)). Duration of Treatment: 6 Weeks